Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03346590
Other study ID # CHU-365
Secondary ID 2017-A01654-49
Status Not yet recruiting
Phase N/A
First received November 15, 2017
Last updated November 20, 2017
Start date November 30, 2017
Est. completion date December 31, 2019

Study information

Verified date November 2017
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 0473751195
Email placarin@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic inflammation in rheumatoid arthritis is associated with adiposity, sarcopenia, cachexia, reduced activity due to functional impairment, and anti-inflammatory drugs. Patients frequently gain weight when taking anti-tumor necrosis factor (TNF) medication, prompting questions about the underlying mechanism and long-term cardiovascular and metabolic tolerance associated with these drugs The primary objective of this study is to analyze the impact of anti-TNF treatment during the first year of administration on the energy metabolism of patients suffering from RA, assessed as an absolute value (before-after) and in comparison with a standard measured in healthy matched subjects.


Description:

Few studies have been focused on the combined evolution of body composition, energy expenditure, physical activity, muscle performance, and nutritional intake in patients taking anti-TNFs.

This study's objective is to assess the impact of anti-TNF treatment during the first year of administration on the energy metabolism of RA patients, measuring variations in basal daily energy expenditure and per type of expenditure using indirect calorimetry with calorimetric chambers. Investigator also aim to define standardized values for RA patients compared to healthy matched controls and to be able to monitor the evolution of these different values during treatment compared to this standard.

This will be an exploratory study with a longitudinal follow-up of the cohort in patients treated in a market authorization context and involving a case/control study. Investigator judged the inclusion of healthy controls justified by the current lack of data comparing the different components of energy metabolism in active RA patients versus healthy subjects using calorimetric chamber measurement. The aim is to obtain reference values to situate RA-specific values in comparison before and after treatment. Investigator considered selecting controls from the RA patients unjustified given how essential it is to commence treatment in active RA cases (1 year with placebo not justifiable). A previously-treated inactive RA population with no inflammation would not be comparable to patients with active RA, and neither would a population with active RA treated with conventional treatment or a different biotherapy to anti-TNFs. Investigator also chose to perform a second assessment at 6 months without calorimetric chamber measurement but rather an indirect measurement using actimetry in order to limit costs and patients lost-to-follow-up due to treatment modification (failure or intolerance), all the while maintaining full assessment at 12 months. Scheduling the assessment at 12 months is justified by published studies' reports of delay before significant weight gain manifests, and enables us to maintain homogeneity as regards variations in physical activity and nutritional intake linked to seasonal changes.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date December 31, 2019
Est. primary completion date October 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- RA patients Women over 18 years old with proven active (DAS28 >3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.

Covered by social security. Capable of giving informed consent and acceding to the requirements of the study.

For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders.

- Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (<25; 25-30; >30).

Exclusion Criteria:

- Refusal to sign consent form.

- Patients under guardianship or curatorship.

- Previous exposure to biological treatment in the course of their disease.

- Suffering from a condition potentially influencing energy metabolism: infection, cancer, diabetes, thyroid dysfunction, psychiatric disorder, current smoker, pregnancy.

- High physical activity level, based on short-form IPAQ questionnaire.

- Variations in weight exceeding 5% of body weight in the previous 6 months.

Study Design


Intervention

Behavioral:
Energy metabolism of patients suffering from RA
Energy metabolism of patients suffering from RA

Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand Centre de Recherche en Nutrition Humaine d'Auvergne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Continuous measurement of energy expenditure and cardiac rhythm in calorimetric chamber Continuous measurement of energy expenditure and cardiac rhythm in calorimetric chamber for 36 hours: at rest, waking, during two physical activity sessions (treadmill walking at 4km/h for 30min), sleeping. for 36 hours
Primary Indirect assessment of energy expenditure Indirect assessment of energy expenditure by measuring physical activity using home actimetry(Armband) under normal living conditions for 4 days and in the calorimetric chamber for calibration. for 4 days
Primary Nutritionist assessment of nutritional intake Nutritionist assessment of nutritional intake during the 2 days preceding energy expenditure measurement. during the 2 days preceding energy expenditure measurement.
Primary Previously-scheduled tests for the RCVRIC protocol at day 1
Secondary Indirect assessment of energy expenditure via measurement of physical activity using calibrated actimetry (Armband) Indirect assessment of energy expenditure via measurement of physical activity using calibrated actimetry (Armband) at home in normal living conditions over 4 days. at 6 months
Secondary Nutritionist evaluation of nutritional intake over 2 days at 6 months
Secondary Previously-scheduled tests for the RCVRIC study protocol (M6): DXA, pQCT, physical strength and performance, physical activity and nutrition questionnaires, cardiovascular risk, serum and urine bank research. at 6 months
See also
  Status Clinical Trial Phase
Completed NCT04472481 - Vitamin D Effect in Rheumatoid Arthritis. Phase 4
Completed NCT00959036 - Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis Phase 1/Phase 2
Completed NCT00913458 - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis Phase 4
Completed NCT01961505 - Topical Compound Tripterygium Wilfordii Hook F for Patients With Active Rheumatoid Arthritis N/A
Completed NCT00393471 - Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis. Phase 3
Terminated NCT02534896 - To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis Phase 3
Completed NCT03172325 - Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA Phase 3
Completed NCT00420199 - A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Phase 3
Completed NCT00882024 - Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA) Phase 2
Completed NCT03599986 - Clinical Efficacy and Safety of Leflunomide in Egyptian Patients With Active Rheumatoid Arthritis
Completed NCT02586246 - Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 Phase 3
Completed NCT01008852 - Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis Phase 2